文献速递前列腺癌

年龄与主动监测后延迟根治性前列腺切除术后不良病理风险的相关性

Association of Age With Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance.
PubMed 文献 · Urology · 2021-06-09

该研究纳入365例初诊为Gleason分级分组1的前列腺癌患者,均先行主动监测后接受延迟根治性前列腺切除术。比较启动主动监测时<65岁与≥65岁患者的不良病理(GG≥3或pT3或pN1)风险,发现≥65岁患者不良病理比例更高(59.2% vs 44.1%,P<0.01),多因素分析年龄≥65岁与不良病理相关(HR 2.21,95%CI 1.57-3.12)。

要点

  • ≥65岁患者延迟根治性前列腺切除术后不良病理风险显著高于<65岁患者。
  • 多因素分析显示年龄≥65岁是不良病理的独立预测因素(HR 2.21)。
  • 在≥65岁组中,mpMRI是不良病理的预测因素(HR 3.33)。

核心结论

  • 年龄≥65岁的前列腺癌GG1患者在接受主动监测后延迟根治性前列腺切除术时,不良病理风险更高。
  • 老年患者可能需要更密切的主动监测,并辅以mpMRI等额外检查以改善风险分层。

研究设计与样本

  • 回顾性研究纳入365例初诊为GG1前列腺癌、先行主动监测后接受延迟根治性前列腺切除术的患者。
  • 按启动主动监测时年龄分为<65岁组和≥65岁组,比较两组不良病理(GG≥3或pT3或pN1)风险。
  • 采用多因素Cox比例风险回归模型计算不同年龄组不良病理的风险。

主要发现

  • 诊断时两组中位前列腺特异抗原密度、阳性活检针数百分比、mpMRI结果或复合基因组分类器评分无显著差异。
  • ≥65岁组不良病理比例为59.2%,<65岁组为44.1%(P<0.01)。
  • ≥65岁组活检升级无生存率和无不良病理生存率更低(log-rank P<0.01)。
  • 多因素分析中年龄≥65岁与不良病理相关(HR 2.21,95%CI 1.57-3.12)。
  • 在≥65岁组中,mpMRI是不良病理的预测因素(HR 3.33,95%CI 1.01-10.95)。

关键数值与推荐

  • 不良病理定义为GG≥3或pT3或pN1。
  • 年龄≥65岁与不良病理的HR为2.21(95%CI 1.57-3.12)。
  • ≥65岁组中mpMRI预测不良病理的HR为3.33(95%CI 1.01-10.95)。

临床怎么用

  • 对≥65岁的前列腺癌GG1患者启动主动监测时,应认识到其延迟手术后不良病理风险较高。
  • 考虑对老年主动监测患者加强监测频率,并利用mpMRI等工具优化风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if older men with Gleason grade group (GG) 1 prostate cancer have a higher risk of having adverse pathology at radical prostatectomy after initially being managed with active surveillance (AS). METHODS: A total of 365 patients with GG1 prostate cancer initially managed with AS followed by delayed radical prostatectomy were identified. The primary outcome was adverse pathology after delayed radical prostatectomy in the men that were <65 years vs. men ≥65 years at the initiation of AS. Adverse pathology was defined as GG ≥3 or pT3 or pN1. Multivariable Cox proportional hazards regression models were used to calculate risk of adverse pathological findings at radical prostatectomy by age group. RESULTS: At diagnosis, there were no significant differences in median prostate specific antigen density, percent positive biopsy cores, multiparametric magnetic resonance imaging (mpMRI) results or composite genomic classifier scores (derived from three commercially available genomic tests) between the two age groups. Men ≥65 years had more adverse pathology at radical prostatectomy (59.2% vs. 44.1%, P <0.01) and lower rates of biopsy upgrade-free survival and adverse pathology-free survival (log-rank P <0.01). On multivariable analysis age ≥65 years (Hazard Ratio (HR) 2.21, 95% Confidence Interval (CI) 1.57, 3.12) was associated with adverse pathology at radical prostatectomy. In separate multivariable analyses done for each age group, mpMRI (HR 3.33, 95% CI 1.01, 10.95) was predictor of adverse pathology in the group ≥65 years. CONCLUSION: Older patients might require closer monitoring on AS and additional testing such as mpMRI might improve their risk stratification.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. de la Calle CM, Shee K, Chu CE, et al. Association of Age With Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance. Urology. 2021. PMID: 34118228. doi:10.1016/j.urology.2021.05.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。